Clinical Trial Update: Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC [Phase 2]

View source ↗

Summary

Phase II trial evaluating adjuvant carboplatin and docetaxel in curatively resected stage I-IIIA non-small cell lung cancer. Results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-06-12